These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

210 related articles for article (PubMed ID: 16051469)

  • 1. Voriconazole activity against clinical yeast isolates: a multicentre Italian study.
    Morace G; Polonelli L;
    Int J Antimicrob Agents; 2005 Sep; 26(3):247-53. PubMed ID: 16051469
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Activity of voriconazole, itraconazole, fluconazole and amphotericin B in vitro against 1763 yeasts from 472 patients in the voriconazole phase III clinical studies.
    Johnson E; Espinel-Ingroff A; Szekely A; Hockey H; Troke P
    Int J Antimicrob Agents; 2008 Dec; 32(6):511-4. PubMed ID: 18790613
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Results from the ARTEMIS DISK Global Antifungal Surveillance study, 1997 to 2005: an 8.5-year analysis of susceptibilities of Candida species and other yeast species to fluconazole and voriconazole determined by CLSI standardized disk diffusion testing.
    Pfaller MA; Diekema DJ; Gibbs DL; Newell VA; Meis JF; Gould IM; Fu W; Colombo AL; Rodriguez-Noriega E;
    J Clin Microbiol; 2007 Jun; 45(6):1735-45. PubMed ID: 17442797
    [TBL] [Abstract][Full Text] [Related]  

  • 4. In vitro activity of voriconazole against Candida species isolated in Taiwan.
    Yang YL; Cheng HH; Lo HJ
    Int J Antimicrob Agents; 2004 Sep; 24(3):294-6. PubMed ID: 15325436
    [TBL] [Abstract][Full Text] [Related]  

  • 5. In vitro investigation of voriconazole susceptibility for keratitis and endophthalmitis fungal pathogens.
    Marangon FB; Miller D; Giaconi JA; Alfonso EC
    Am J Ophthalmol; 2004 May; 137(5):820-5. PubMed ID: 15126145
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of disk diffusion test and Etest for voriconazole and fluconazole susceptibility testing.
    Buchta V; Vejsova M; Vale-Silva LA
    Folia Microbiol (Praha); 2008; 53(2):153-60. PubMed ID: 18837162
    [TBL] [Abstract][Full Text] [Related]  

  • 7. In vitro activity of isavuconazole against Trichosporon, Rhodotorula, Geotrichum, Saccharomyces and Pichia species.
    Thompson GR; Wiederhold NP; Sutton DA; Fothergill A; Patterson TF
    J Antimicrob Chemother; 2009 Jul; 64(1):79-83. PubMed ID: 19406849
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Potential fungicidal effect of voriconazole against Candida spp.
    Rubio MC; de Ocáriz IR; Gil J; Benito R; Rezusta A
    Int J Antimicrob Agents; 2005 Mar; 25(3):264-7. PubMed ID: 15737524
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparative evaluation of the Vitek 2 yeast susceptibility test and CLSI broth microdilution reference method for testing antifungal susceptibility of invasive fungal isolates in Italy: the GISIA3 study.
    Borghi E; Iatta R; Sciota R; Biassoni C; Cuna T; Montagna MT; Morace G
    J Clin Microbiol; 2010 Sep; 48(9):3153-7. PubMed ID: 20631105
    [TBL] [Abstract][Full Text] [Related]  

  • 10. In vitro activities of voriconazole (UK-109, 496), fluconazole, itraconazole and amphotericin B against 132 non-albicans bloodstream yeast isolates (CANARI study).
    Swinne D; Watelle M; Van der Flaes M; Nolard N
    Mycoses; 2004 Jun; 47(5-6):177-83. PubMed ID: 15189180
    [TBL] [Abstract][Full Text] [Related]  

  • 11. In vitro susceptibility of Candida species to five antifungal agents in a German university hospital assessed by the reference broth microdilution method and Etest.
    Fleck R; Dietz A; Hof H
    J Antimicrob Chemother; 2007 Apr; 59(4):767-71. PubMed ID: 17293369
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [In vitro susceptibility of fungal and yeast clinical isolates to itraconazole and voriconazole].
    Morera-López Y; Torres-Rodríguez JM; Jiménez-Cabello T
    Rev Iberoam Micol; 2005 Jun; 22(2):105-9. PubMed ID: 16107169
    [TBL] [Abstract][Full Text] [Related]  

  • 13. In vitro activity of isavuconazole against 140 reference fungal strains and 165 clinically isolated yeasts from Japan.
    Yamazaki T; Inagaki Y; Fujii T; Ohwada J; Tsukazaki M; Umeda I; Kobayashi K; Shimma N; Page MG; Arisawa M
    Int J Antimicrob Agents; 2010 Oct; 36(4):324-31. PubMed ID: 20674282
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A global evaluation of voriconazole activity tested against recent clinical isolates of Candida spp.
    Diekema DJ; Messer SA; Hollis RJ; Boyken L; Tendolkar S; Kroeger J; Jones RN; Pfaller MA
    Diagn Microbiol Infect Dis; 2009 Feb; 63(2):233-6. PubMed ID: 19070452
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [In vitro activity of voriconazole against yeast and algae isolates according to new resistance pattern cut-off points].
    Pemán J; Cantón E; Calabuig E; Bosch M; Valentí A; Viudes A; Gobernado M
    Rev Esp Quimioter; 2006 Mar; 19(1):21-33. PubMed ID: 16688288
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Susceptibility of fungi isolated from clinical materials to voriconazole].
    Pawlik B; Szul A; Macura AB
    Med Dosw Mikrobiol; 2006; 58(2):155-61. PubMed ID: 17133909
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical evaluation of a dried commercially prepared microdilution panel for antifungal susceptibility testing of five antifungal agents against Candida spp. and Cryptococcus neoformans.
    Pfaller MA; Boyken L; Hollis RJ; Messer SA; Tendolkar S; Diekema DJ
    Diagn Microbiol Infect Dis; 2004 Oct; 50(2):113-7. PubMed ID: 15474320
    [TBL] [Abstract][Full Text] [Related]  

  • 18. In vitro fluconazole susceptibility of 1565 clinical isolates of Candida species evaluated by the disk diffusion method performed using NCCLS M44-A guidelines.
    Testore GP; Dori L; Buonomini AR; Schito GC; Soro O; Fortina G; Andreoni S; Carlone N; Tullio V; Andreoni M
    Diagn Microbiol Infect Dis; 2004 Nov; 50(3):187-92. PubMed ID: 15541604
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Activities of fluconazole and voriconazole against bloodstream isolates of Candida glabrata and Candida krusei: a 14-year study in a Spanish tertiary medical centre.
    Quindós G; Sánchez-Vargas LO; Villar-Vidal M; Eraso E; Alkorta M; Hernández-Almaraz JL
    Int J Antimicrob Agents; 2008 Mar; 31(3):266-71. PubMed ID: 18054468
    [TBL] [Abstract][Full Text] [Related]  

  • 20. In vitro activities of voriconazole, posaconazole, and fluconazole against 4,169 clinical isolates of Candida spp. and Cryptococcus neoformans collected during 2001 and 2002 in the ARTEMIS global antifungal surveillance program.
    Pfaller MA; Messer SA; Boyken L; Hollis RJ; Rice C; Tendolkar S; Diekema DJ
    Diagn Microbiol Infect Dis; 2004 Mar; 48(3):201-5. PubMed ID: 15023430
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.